Neurosense Therapeutics Ltd reports results for the quarter ended in March - Earnings Summary
24/06/2024 14:54
* Neurosense Therapeutics Ltd NRSN.OQ reported a quarterly
adjusted loss of 35 cents per share for the quarter ended in
March. The mean expectation of two analysts for the quarter was
for a loss of 20 cents per share. Wall Street expected
results to range from -22 cents to -19 cents per share.
* Reported revenue was zero; analysts expected zero.
* Neurosense Therapeutics Ltd's reported EPS for the quarter
was a
loss of 35 cents.
* The company reported a quarterly loss of $5.4 million.
* Neurosense Therapeutics Ltd shares had fallen by 50.7%
this
quarter and gained 14.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 7.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Neurosense
Therapeutics Ltd is $5.25
This summary was machine generated from LSEG data June 24 at
01:54 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.20 -0.35 Missed
Dec. 31 2023 -0.20 -0.16 Beat
Sep. 30 2023 -0.24 0.10 Beat
Jun. 30 2023 -0.28 -0.44 Missed